Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody

Sabrina Oliveira, Guus A M S Van Dongen, Marijke Stigter-Van Walsum, Rob C. Roovers, Jord C. Stam, Willem Mali, Paul J. Van Diest, Paul M P Van Bergen En Henegouwen

Research output: Contribution to journalArticle

Abstract

Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types of human epithelial cancers, noninvasive molecular imaging of this receptor is of great interest. A number of studies have employed monoclonal antibodies as probes; however, their characteristic long half-life in the bloodstream has encouraged the development of smaller probes. In this study, an anti-EGFR nanobody-based probe was developed and tested in comparison with cetuximab for application in optical molecular imaging. To this aim, the anti-EGFR nanobody 7D12 and cetuximab were conjugated to the near-infrared fluorophore IRDye800CW. 7D12-IR allowed the visualization of tumors as early as 30 minutes postinjection, whereas with cetuximab-IR, no signal above background was observed at the tumor site. Quantification of the IR-conjugated proteins in the tumors revealed <17% of injected dose per gram 2 hours after injection of 7D12-IR, which was significantly higher than the tumor uptake obtained 24 hours after injection of cetuximab-IR. This difference is associated with the superior penetration and distribution of 7D12-IR within the tumor. These results demonstrate that this anti-EGFR nanobody conjugated to the NIR fluorophore has excellent properties for rapid preclinical optical imaging, which holds promise for its future use as a complementary diagnostic tool in humans.

Original languageEnglish (US)
Pages (from-to)33-46
Number of pages14
JournalMolecular Imaging
Volume11
Issue number1
DOIs
StatePublished - Jan 2012
Externally publishedYes

Fingerprint

Single-Domain Antibodies
Optical Imaging
Epidermal Growth Factor Receptor
Heterografts
Tumors
tumors
Visualization
Infrared radiation
Imaging techniques
Molecular imaging
Fluorophores
Neoplasms
Molecular Imaging
probes
injection
Monoclonal antibodies
Injections
antibodies
half life
penetration

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging
  • Biotechnology
  • Molecular Medicine
  • Biomedical Engineering
  • Condensed Matter Physics

Cite this

Oliveira, S., Van Dongen, G. A. M. S., Stigter-Van Walsum, M., Roovers, R. C., Stam, J. C., Mali, W., ... Van Bergen En Henegouwen, P. M. P. (2012). Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Molecular Imaging, 11(1), 33-46. https://doi.org/10.2310/7290.2011.00025

Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. / Oliveira, Sabrina; Van Dongen, Guus A M S; Stigter-Van Walsum, Marijke; Roovers, Rob C.; Stam, Jord C.; Mali, Willem; Van Diest, Paul J.; Van Bergen En Henegouwen, Paul M P.

In: Molecular Imaging, Vol. 11, No. 1, 01.2012, p. 33-46.

Research output: Contribution to journalArticle

Oliveira, S, Van Dongen, GAMS, Stigter-Van Walsum, M, Roovers, RC, Stam, JC, Mali, W, Van Diest, PJ & Van Bergen En Henegouwen, PMP 2012, 'Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody', Molecular Imaging, vol. 11, no. 1, pp. 33-46. https://doi.org/10.2310/7290.2011.00025
Oliveira, Sabrina ; Van Dongen, Guus A M S ; Stigter-Van Walsum, Marijke ; Roovers, Rob C. ; Stam, Jord C. ; Mali, Willem ; Van Diest, Paul J. ; Van Bergen En Henegouwen, Paul M P. / Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. In: Molecular Imaging. 2012 ; Vol. 11, No. 1. pp. 33-46.
@article{cbd889b99c724f098cb32e8fb5edc30e,
title = "Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody",
abstract = "Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types of human epithelial cancers, noninvasive molecular imaging of this receptor is of great interest. A number of studies have employed monoclonal antibodies as probes; however, their characteristic long half-life in the bloodstream has encouraged the development of smaller probes. In this study, an anti-EGFR nanobody-based probe was developed and tested in comparison with cetuximab for application in optical molecular imaging. To this aim, the anti-EGFR nanobody 7D12 and cetuximab were conjugated to the near-infrared fluorophore IRDye800CW. 7D12-IR allowed the visualization of tumors as early as 30 minutes postinjection, whereas with cetuximab-IR, no signal above background was observed at the tumor site. Quantification of the IR-conjugated proteins in the tumors revealed <17{\%} of injected dose per gram 2 hours after injection of 7D12-IR, which was significantly higher than the tumor uptake obtained 24 hours after injection of cetuximab-IR. This difference is associated with the superior penetration and distribution of 7D12-IR within the tumor. These results demonstrate that this anti-EGFR nanobody conjugated to the NIR fluorophore has excellent properties for rapid preclinical optical imaging, which holds promise for its future use as a complementary diagnostic tool in humans.",
author = "Sabrina Oliveira and {Van Dongen}, {Guus A M S} and {Stigter-Van Walsum}, Marijke and Roovers, {Rob C.} and Stam, {Jord C.} and Willem Mali and {Van Diest}, {Paul J.} and {Van Bergen En Henegouwen}, {Paul M P}",
year = "2012",
month = "1",
doi = "10.2310/7290.2011.00025",
language = "English (US)",
volume = "11",
pages = "33--46",
journal = "Molecular Imaging",
issn = "1535-3508",
publisher = "Decker Publishing",
number = "1",

}

TY - JOUR

T1 - Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody

AU - Oliveira, Sabrina

AU - Van Dongen, Guus A M S

AU - Stigter-Van Walsum, Marijke

AU - Roovers, Rob C.

AU - Stam, Jord C.

AU - Mali, Willem

AU - Van Diest, Paul J.

AU - Van Bergen En Henegouwen, Paul M P

PY - 2012/1

Y1 - 2012/1

N2 - Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types of human epithelial cancers, noninvasive molecular imaging of this receptor is of great interest. A number of studies have employed monoclonal antibodies as probes; however, their characteristic long half-life in the bloodstream has encouraged the development of smaller probes. In this study, an anti-EGFR nanobody-based probe was developed and tested in comparison with cetuximab for application in optical molecular imaging. To this aim, the anti-EGFR nanobody 7D12 and cetuximab were conjugated to the near-infrared fluorophore IRDye800CW. 7D12-IR allowed the visualization of tumors as early as 30 minutes postinjection, whereas with cetuximab-IR, no signal above background was observed at the tumor site. Quantification of the IR-conjugated proteins in the tumors revealed <17% of injected dose per gram 2 hours after injection of 7D12-IR, which was significantly higher than the tumor uptake obtained 24 hours after injection of cetuximab-IR. This difference is associated with the superior penetration and distribution of 7D12-IR within the tumor. These results demonstrate that this anti-EGFR nanobody conjugated to the NIR fluorophore has excellent properties for rapid preclinical optical imaging, which holds promise for its future use as a complementary diagnostic tool in humans.

AB - Given that overexpression of the epidermal growth factor receptor (EGFR) is found in many types of human epithelial cancers, noninvasive molecular imaging of this receptor is of great interest. A number of studies have employed monoclonal antibodies as probes; however, their characteristic long half-life in the bloodstream has encouraged the development of smaller probes. In this study, an anti-EGFR nanobody-based probe was developed and tested in comparison with cetuximab for application in optical molecular imaging. To this aim, the anti-EGFR nanobody 7D12 and cetuximab were conjugated to the near-infrared fluorophore IRDye800CW. 7D12-IR allowed the visualization of tumors as early as 30 minutes postinjection, whereas with cetuximab-IR, no signal above background was observed at the tumor site. Quantification of the IR-conjugated proteins in the tumors revealed <17% of injected dose per gram 2 hours after injection of 7D12-IR, which was significantly higher than the tumor uptake obtained 24 hours after injection of cetuximab-IR. This difference is associated with the superior penetration and distribution of 7D12-IR within the tumor. These results demonstrate that this anti-EGFR nanobody conjugated to the NIR fluorophore has excellent properties for rapid preclinical optical imaging, which holds promise for its future use as a complementary diagnostic tool in humans.

UR - http://www.scopus.com/inward/record.url?scp=84857266262&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84857266262&partnerID=8YFLogxK

U2 - 10.2310/7290.2011.00025

DO - 10.2310/7290.2011.00025

M3 - Article

C2 - 22418026

AN - SCOPUS:84857266262

VL - 11

SP - 33

EP - 46

JO - Molecular Imaging

JF - Molecular Imaging

SN - 1535-3508

IS - 1

ER -